Vera Therapeutics, Inc. $VERA Shares Bought by Hudson Bay Capital Management LP

Hudson Bay Capital Management LP increased its position in Vera Therapeutics, Inc. (NASDAQ:VERA) by 47.4% during the third quarter, HoldingsChannel.com reports. The fund owned 440,591 shares of the company’s stock after acquiring an additional 141,615 shares during the quarter. Hudson Bay Capital Management LP’s holdings in Vera Therapeutics were worth $12,804,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of the company. Deerfield Management Company L.P. boosted its stake in shares of Vera Therapeutics by 8.8% during the third quarter. Deerfield Management Company L.P. now owns 3,641,157 shares of the company’s stock valued at $105,812,000 after acquiring an additional 293,040 shares during the last quarter. Vanguard Group Inc. raised its stake in Vera Therapeutics by 6.3% in the 3rd quarter. Vanguard Group Inc. now owns 3,190,653 shares of the company’s stock valued at $92,720,000 after purchasing an additional 189,545 shares during the last quarter. Vestal Point Capital LP raised its stake in Vera Therapeutics by 24.0% in the 2nd quarter. Vestal Point Capital LP now owns 3,100,000 shares of the company’s stock valued at $73,036,000 after purchasing an additional 600,000 shares during the last quarter. Integral Health Asset Management LLC lifted its holdings in Vera Therapeutics by 47.8% in the 3rd quarter. Integral Health Asset Management LLC now owns 1,700,000 shares of the company’s stock valued at $49,402,000 after purchasing an additional 550,000 shares in the last quarter. Finally, Geode Capital Management LLC boosted its stake in shares of Vera Therapeutics by 7.7% during the 2nd quarter. Geode Capital Management LLC now owns 1,294,958 shares of the company’s stock worth $30,513,000 after purchasing an additional 92,149 shares during the last quarter. 99.21% of the stock is owned by hedge funds and other institutional investors.

Vera Therapeutics Trading Up 8.0%

NASDAQ VERA opened at $41.37 on Friday. The firm has a market capitalization of $2.90 billion, a price-to-earnings ratio of -8.88 and a beta of 1.17. The company has a debt-to-equity ratio of 0.12, a quick ratio of 13.64 and a current ratio of 13.64. Vera Therapeutics, Inc. has a one year low of $18.53 and a one year high of $56.05. The company’s 50 day moving average price is $43.19 and its 200 day moving average price is $37.24.

Vera Therapeutics (NASDAQ:VERA) last released its quarterly earnings data on Thursday, February 26th. The company reported ($1.39) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.34) by ($0.05). During the same period in the prior year, the business earned ($0.72) EPS. On average, sell-side analysts predict that Vera Therapeutics, Inc. will post -2.89 EPS for the current year.

Insider Transactions at Vera Therapeutics

In other Vera Therapeutics news, insider Laurence Matthew Skelton sold 1,582 shares of the firm’s stock in a transaction dated Monday, February 23rd. The stock was sold at an average price of $41.98, for a total value of $66,412.36. Following the transaction, the insider directly owned 64,218 shares of the company’s stock, valued at $2,695,871.64. This trade represents a 2.40% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider William D. Turner sold 2,187 shares of the business’s stock in a transaction dated Monday, February 23rd. The stock was sold at an average price of $41.98, for a total value of $91,810.26. Following the transaction, the insider owned 45,313 shares in the company, valued at approximately $1,902,239.74. This represents a 4.60% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 33,490 shares of company stock worth $1,405,910 in the last quarter. 16.30% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on VERA. JPMorgan Chase & Co. cut their price objective on shares of Vera Therapeutics from $99.00 to $96.00 and set an “overweight” rating for the company in a research report on Friday, December 19th. Wedbush lifted their target price on shares of Vera Therapeutics from $23.00 to $33.00 and gave the stock a “neutral” rating in a research note on Thursday, December 11th. TD Cowen reiterated a “buy” rating on shares of Vera Therapeutics in a report on Friday, December 5th. Bank of America raised their price objective on Vera Therapeutics from $48.00 to $66.00 and gave the stock a “buy” rating in a report on Friday, December 19th. Finally, Evercore lifted their price objective on Vera Therapeutics from $75.00 to $97.00 and gave the company an “outperform” rating in a research report on Monday, December 8th. Ten investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $81.45.

About Vera Therapeutics

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.